To the Editor
25–30% of younger adults with newly diagnosed acute myeloid leukemia (AML) carry internal tandem duplications (ITDs) in the FLT3 gene [1]. ITD mutations regularly occur in exons 14 and 15 of FLT3, affecting JMD and TKD1 regions and causing conformational changes leading to the constitutive activation of the receptor tyrosine kinase [2]. These mutations are associated with poor prognosis and current therapeutic options include induction therapy (cytarabine and daunorubicine) followed by consolidation (cytarabine monotherapy) in combination with midostaurin, which is a tyrosine kinase inhibitor targeting FLT3 [3].
Combination of chemotherapy with FLT3 inhibitors has been shown to improve progression free survival in patients carrying the ITD in the JMD domain of FLT3. On the contrary, chemotherapeutic resistance has been associated with insertion of the ITD in the TKD region, which, therefore, represents an unfavorable prognostic factor for relapse and overall survival (OS) [2, 4]. Accordingly, we and others have demonstrated that ITD-TKD cell lines and primary mouse bone marrow cells show reduced apoptosis in response to different FLT3 inhibitors (i.e., gilteritinib and quizartinib) when compared to their ITD-JMD counterpart [5,6,7,8]. Moreover, recently we have also identified the molecular mechanisms driving resistant of ITD-TKD cells towards FLT3 inhibitors, further underlining the importance of a genotype-specific treatment for FLT3-ITD patients [8]. In contrast, impact of the distinct locations of the ITD-mutations on chemotherapeutic drugs sensitivity still remains a matter of current debate.
To address this question, we aimed at (i) investigating whether the ITD insertion sites influence responsiveness towards cytarabine (Ara-C) treatment in AML cell lines and patient-derived primary AML blasts, at (ii) elucidating the molecular mechanisms controlling Ara-C sensitivity, and at (iii) identifying novel potential therapeutic strategies to revert resistance in ITD-TKD AML cells.
To assess for differential drug sensitivity depending on ITD-location, we treated stably transfected hematopoietic Ba/F3 and 32D cells expressing the mutant FLT3 receptors carrying the ITD either in the JM or TK domains (FLT3ITD-JMD and FLT3ITD-TKD) with Ara-C at clinically-relevant doses. In fact, FLT3ITD-JMD cells were more susceptible towards in vitro Ara-C-mediated killing as compared to their FLT3ITD-TKD counterpart (Fig. 1A). These effects were reproducible in two different cellular backgrounds (Ba/F3 and 32D cells) after 24 h of 20 µM Ara-C exposure (Fig. S1), confirming that the ITD-location determines sensitivity towards chemotherapy. Then, we investigated whether such distinct sensitivity could also be recapitulated in a setting closer resembling the clinical situation. To do so, we took advantage of a small cohort of FLT3-ITD AML patients, which we have previously classified in two main groups according to the ITD insertion site: 3 FLT3ITD-TKD patients (carrying the ITD in the TKD domain) and 3 FLT3ITD-JMD+ITD-TKD patients (carrying the ITD in the JMD and TKD domain) [8] (Fig. S2). Remarkably, genetic stratification based on the ITD localization reflected the drug-response phenotype: FLT3ITD-JMD+ITD-TKD blasts showed higher sensitivity to Ara-C in cell death analysis, while induction of apoptosis was barely detected in FLT3ITD-TKD blasts at 1 µM Ara-C (Fig. 1B). This result suggests that the pro-apoptotic effect of the ITD insertion within the JM domain is dominant over its ITD-TKD counterpart. This observation is consistent with recently published retrospective analyses showing that patients with insertions in JMD and/or in JMD and TKD1 had a significantly improved OS and a lower relapse rate as compared to patients with insertion sites in TKD1 [4].
Ara-C is an antineoplastic agent, which kills replicating cells by inhibiting DNA synthesis and generating DNA damage-double stranded breaks (DSBs) [9]. Given the role of FLT3-ITD in the regulation of DNA damage response genes [10, 11], we next investigated whether FLT3-ITD insertion sites may differently impact intrinsic and Ara-C-induced DNA damage. First, we assessed the levels of γ-H2AX, a widely used biomarker of DNA damage, in FLT3ITD-JMD and FLT3ITD-TKD cells under steady-state conditions. Interestingly, untreated FLT3ITD-TKD cells show higher level of DNA damage as compared to FLT3ITD-JMD cells, and as revealed by evaluating phosphorylated histone γ-H2AX (Fig. 1C, left panel) and neutral comet assays, that detect DSBs (Fig. 1C, right panel, Fig. S3). Increased intrinsic DNA damage has been linked to accumulation of reactive oxygen species (ROS). Indeed, when comparing intracellular ROS levels under steady state conditions, we found stronger ROS accumulation in FLT3ITD-TKD cells (Fig. S4). Importantly, following Ara-C treatment, we observed that FLT3ITD-TKD cells accumulated significantly less DNA damage than FLT3ITD-JMD cells (fold change FLT3ITD-JMD = 2.03, fold change FLT3ITD-TKD = 0.94) (Fig. 1C).
Next, we asked whether differences in DNA damage seen in our two FLT3-ITD cell types correlated with a DNA repair efficacy. To examine the DNA repair efficacy, following 24 h Ara-C exposure, FLT3-ITD cells were cultured in drug-free medium for 0–24 h and DNA damage was analyzed at consecutive time points. Both γH2AX flow cytometry staining and comet assay showed similar results. Under steady-state conditions, FLT3ITD-TKD cells showed higher levels of DNA damage than FLT3ITD-JMD cells (Fig. 1D). Thereafter, DNA damage levels decreased as the extent of DNA repair was similar in both FLT3ITD-JMD and FLT3ITD-TKD cells (Fig. 1D). Taken together, our observations indicate that the FLT3-ITD insertion site impacts responsiveness to Ara-C treatment, without affecting DNA repair.
To elucidate the molecular mechanisms underlying the different sensitivity to Ara-C therapy in FLT3-ITD cells, we applied state-of-the-art, high-sensitive, mass spectrometry (MS)-based (phospho)proteomics followed by our recently developed modeling pipeline “SignalingProfiler” (Fig. 2A) (https://github.com/SaccoPerfettoLab/SignalingProfiler) [10]. This strategy enables us to obtain cell-specific models, that can be explored by performing gene ontology enrichment analysis [12].
As a first step in our approach, we have profiled the Ara-C-dependent modulation at the global proteome and phosphoproteome level in FLT3ITD-TKD and FLT3ITD-JMD cells by employing MS-based (phospho)proteomics. Using this strategy, about 4000 proteins (Table S1, Fig. S5A) and more than 13,000 phosphorylation events (class I sites, Table S2, Fig. S5B) were quantified. The biological triplicates were highly correlated with Pearson correlation coefficients ranging between 0.75 (for phospho measurements) (Fig. S5D) and 0.97 (for proteome measurements) (Fig. S5C).
Next, we applied a statistical t-test to narrow-down factors that are regulated by Ara-C treatment in the two FLT3-ITD mutant cell lines. Briefly, about 10% of the proteome and 15% phosphoproteome displayed a significant (FDR < 0.1) change upon Ara-C treatment (Tables S1, S2). Comparative analysis of significantly modulated proteins or phosphosites, revealed a common core (115 proteins and 89 phosphosites) of targets significantly altered by 24 h of Ara-C treatment, regardless of the ITD insertion site (Fig. S6A).
To elucidate the biological processes globally modulated by Ara-C treatment at the proteome layer, we performed an unsupervised hierarchical clustering that enabled us to separate the significantly modulated proteins in four main clusters (Fig. S6B; Table S2). We checked for biological processes altered in the four identified clusters by performing a gene ontology term enrichment analysis (FDR < 0.05) [13]. Interestingly, we found that Ara-C treatment positively regulates proteins significantly enriched in cell cycle and mitosis processes only in FLT3ITD-TKD cells (Fig. S6B, bar graph).
Next, we used gene ontology term enrichment analysis to characterize the Ara-C-dependent modulation of the phosphoproteome in FLT3-ITD cells. From this analysis no differences between biological processes and pathways enriched in Ara-C treated FLT3ITD-TKD and FLT3ITD-JMD cells could be detected (Fig. S7A). On the contrary, our kinase substrate motif enrichment analysis revealed that cell cycle kinases, including CDKs and Aurora kinase, were significantly upregulated only in treated FLT3ITD-TKD cells. Consistently with our proteomic data, core kinases involved in DNA damage response, including ATM, DNA-PK and CHK1, were similarly upregulated in Ara-C treated FLT3-ITD cells (Fig. S7B). To further corroborate our observations, we analyzed the levels of key proteins involved in DNA damage response. As shown in Fig. S8, Ara-C similarly trigger the DNA damage response pathway in FLT3-ITD cells, regardless of the ITD insertion site. This observation is consistent with the comparable ability of FLT3-ITD cells to repair damaged DNA (Fig. S7). In fact, these findings only provide a fragmented and vague picture of the processes involved in the cellular response to Ara-C, and point out the need for an unbiased, system-level approach able to produce more granular information regarding the molecular events involved. Thus, we exploited SignalingProfiler, a computational method that combines multi-omic data with literature-derived signaling networks of causal interactions to extract context-specific models of signal transduction [8]. Signaling Profiler first allowed us to infer the activity of 49 kinases, 4 phosphatases, 22 transcription factors and 156 other entities, in each cell line (Table S3). As shown in Fig. S7C, the correlation between the inferred activity of these signaling proteins in FLT3ITD-JMD and FLT3ITD-TKD is poor, suggesting that the different ITD insertion sites likely rewire signaling networks. Next, we derived FLT3ITD-JMD and FLT3ITD-TKD specific mechanistic models, consisting of 146 nodes and 183 edges (Figs. S9–S10), and we looked at the biological processes enriched by the proteins of the two models (Table S4) through gProfiler [12] (adjusted p < 0.05) (Table S4). Interestingly, this analysis resulted in the identification of cell cycle related terms upregulated in the FLT3ITD-TKD model, confirming our previous findings [8] (Fig. 2B, panel a). A deep inspection of the generated models revealed that Ara-C treatment upregulates the CDK2-CCNA2 (Cyclin A2) only in FLT3ITD-TKD cells (Fig. 2B, panel b). Thus, we speculated that CDK2-Cyclin A2 axis may play a role in Ara-C sensitivity by impacting cell cycle progression through the CDK7-Cyclin H activation (Fig. 2C, right panel).
First, we confirmed that in Ara-C treated FLT3ITD-TKD cells expression of CDK2 and Cyclin H was significantly increased as compared to their FLT3ITD-JMD counterparts (Fig. 2C, Fig. S11A). Consistently, our cell cycle analysis and EdU incorporation assay revealed that upon Ara-C treatment FLT3ITD-TKD cells are significantly more accumulated in the S phase as compared to FLT3ITD-JMD cells (Fig. 2C, left panel, Fig. S11B). Although Ara-C has been characterized as an S phase-specific chemotherapeutic drug, different cell types have been shown to be arrested in distinct phases of the cell cycle by Ara-C [14]. The differential cell cycle arrest has been shown to affect the severity of induced DNA damage and the pro-apoptotic efficacy. Therefore, we investigated whether pharmacological inhibition of CDK7 could increase the FLT3ITD-TKD cells responsiveness to Ara-C treatment in both patients-derived FLT3-ITD primary blasts and Ba/F3 cells. As shown in Fig. 2D and S12A, our apoptotic and cell viability experiments show that Ara-C treatment in combination with THZ1, a highly selective CDK7 inhibitor, increases the sensitivity of FLT3ITD-TKD cells. Additionally, our data suggest that while in FLT3ITD-JMD cells Ara-C and THZ1 drugs seems to have a synergistic effect on apoptosis, in FLT3ITD-TKD cells they have an additive effect (Fig. S12C).
Taken together, our findings confirm the clinical relevance of the FLT3-ITD location, which affects disease biology. In our study, ITD-location alters the intrinsic DNA damage level and sensitivity to cytarabine treatment in both AML cell lines and patient-derived primary AML blasts. We recently showed that different FLT3-ITD insertion sites alter sensitivity to TKIs treatment through the modulation of WEE1-CDK1 axis and cell cycle progression [8]. Applying the SignalingProfiler pipeline to our phosphoproteomic data revealed that Ara-C responsiveness is associated to the deregulation of the CDK2-CDK7 pathway and consequent accumulation of cells in the S phase. Pharmacological suppression of CDK7 synergistically acts with cytarabine, restoring the FLT3ITD-TKD cells’ sensitivity. This observation is consistent with recent studies reporting that CDK7 inhibitor potentiates the anti-cancer effect of DNA damage agents or tyrosine kinase inhibitor as potent anti-cancer agents [15]. Finally, the ITD dependent differences in cell cycle progression may facilitate therapeutic strategies to sensitize FLT3ITD-TKD cells to chemotherapy, however, these pathways need to be investigated more in depth in further pre-clinical studies.
Data availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD038638. Reviewer account details: Username: reviewer_pxd038638@ebi.ac.uk. Password: ckwYX9wz.
References
Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312.
Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114:2386–92.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I. et al. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2022;36:90–9.
Pugliese GM, Latini S, Massacci G, Perfetto L, Sacco F. Combining mass spectrometry-based phosphoproteomics with a network-based approach to reveal flt3-dependent mechanisms of chemoresistance. Proteomes. 2021;9:19.
Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood. 2009;113:4074–7.
Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, et al. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia. 2016;30:1220–5.
Massacci G, Venafra V, Latini S, Bica V, Pugliese GM, Graziosi S, et al. A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients. Leukemia. 2022. Available from: https://doi.org/10.1038/s41375-022-01785-w.
Pourrajab F, Zare-Khormizi MR, Hekmatimoghaddam S, Hashemi AS. Molecular targeting and rational chemotherapy in acute myeloid leukemia. J Exp Pharm. 2020;12:107–28.
Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, et al. Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells PARP1 inhibitors. Blood. 2018;132:67–77.
Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, et al. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia. 2006;20:2130–6.
Reimand J, Kull M, Peterson H, Hansen J, Vilo J. G:Profiler-a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res. 2007;35:193–200.
Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13:731–40.
Wang X, Chen Z, Mishra AK, Silva A, Ren W, Pan Z, et al. Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to wee1 inhibition. Haematologica. 2018;103:466–76.
Kuo K-L, Lin W-C, Liu S-H, Hsu F-S, Kuo Y, Liao S-M, et al. THZ1, a covalent CDK7 inhibitor, enhances gemcitabine-induced cytotoxicity via suppression of Bcl-2 in urothelial carcinoma. Am J Cancer Res. 2021;11:171–80. Available from: https://pubmed.ncbi.nlm.nih.gov/33520367/.
Acknowledgements
We thank Prof. Gianni Cesareni and Prof. Luisa Castagnoli for their essential scientific input. Dr. Serena Paoluzi and Dr. Marta Iannuccelli for their technical support. We thank Dr. Grumati and the MS facility at TIGEM for their scientific and technical support.
Funding
This research was funded by the Italian association for cancer research (AIRC) with a grant to FS (Start-Up Grant n. 21815). VV is supported by MUR, GMP, and VB are supported by the AIRC Start up grant number 21815.
Author information
Authors and Affiliations
Contributions
Conceptualization: GMP, FS; methodology: GMP, VV, VB, GM, LP, FS; formal analysis: GMP, VV, VB, GM, VB, SL, SG; investigation: GMP, VV, with the contribution of FS, LP, GM, VB, SL, SG; writing original draft preparation: GMP, FS, LP; resources: FS; writing review and editing: GMP, TF, FS, LP; supervision: FS; funding acquisition: FS. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Pugliese, G.M., Venafra, V., Bica, V. et al. Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach. Leukemia 37, 1151–1155 (2023). https://doi.org/10.1038/s41375-023-01881-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-023-01881-5